C4 Therapeutics (NASDAQ:CCCC) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
0
2
0
0
Last 30D
1
0
1
0
0
1M Ago
0
0
0
0
0
2M Ago
0
0
0
0
0
3M Ago
1
0
1
0
0
In the assessment of 12-month price targets, analysts unveil insights for C4 Therapeutics, presenting an average target of $10.75, a high estimate of $14.00, and a low estimate of $8.00. This upward trend is evident, with the current average reflecting a 30.3% increase from the previous average price target of $8.25.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture of C4 Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Derek Archila
Wells Fargo
Raises
Equal-Weight
$8.00
$7.00
Bradley Canino
Stifel
Raises
Buy
$14.00
$13.00
Terence Flynn
Morgan Stanley
Raises
Equal-Weight
$8.00
$1.00
Bradley Canino
Stifel
Raises
Buy
$13.00
$12.00
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to ...Full story available on Benzinga.com
Benzinga
